Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort

被引：0
|
作者：
Majd Issa
Brett G. Klamer
Nikol Mladkova
Georgios I. Laliotis
Vidhya Karivedu
Priyanka Bhateja
Chase Byington
Khaled Dibs
Xueliang Pan
Arnab Chakravarti
John Grecula
Sachin R. Jhawar
Darrion Mitchell
Sujith Baliga
Matthew Old
Ricardo L. Carrau
James W. Rocco
Dukagjin M. Blakaj
Marcelo Bonomi
机构：
[1] The Ohio State University Wexner Medical Center,Department of Internal Medicine, Division of Medical Oncology
[2] The Ohio State University,Center for Biostatistics, Department of Biomedical Informatics
[3] The Ohio State University Wexner Medical Center,Division of Radiation Oncology
[4] Johns Hopkins University,Sidney Kimmel Comprehensive Cancer Center and Department of Oncology
[5] The Ohio State University Wexner Medical Center,Department of Otolaryngology
来源：
BMC Cancer | / 22卷
关键词：
Head and neck cancer; Head and neck squamous cell carcinoma; Immunotherpay; Immune checkpoint inhibitors; Survival in head and neck cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort
    Issa, Majd
    Klamer, Brett G.
    Mladkova, Nikol
    Laliotis, Georgios I.
    Karivedu, Vidhya
    Bhateja, Priyanka
    Byington, Chase
    Dibs, Khaled
    Pan, Xueliang
    Chakravarti, Arnab
    Grecula, John
    Jhawar, Sachin R.
    Mitchell, Darrion
    Baliga, Sujith
    Old, Matthew
    Carrau, Ricardo L.
    Rocco, James W.
    Blakaj, Dukagjin M.
    Bonomi, Marcelo
    BMC CANCER, 2022, 22 (01)
  • [2] Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
    Miyamoto, Noriyuki
    Takenaka, Yukinori
    Sudo, Takato
    Eguchi, Hirotaka
    Tanaka, Hidenori
    Fukusumi, Takahito
    Takemoto, Norihiko
    Suzuki, Motoyuki
    Inohara, Hidenori
    ACTA OTO-LARYNGOLOGICA, 2023, 143 (10) : 925 - 930
  • [3] Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
    Pan, Cassie
    Ng, Kevin
    Voutsinas, Jenna
    Barber, Brittany
    Rizvi, Zain H.
    Marchiano, Emily
    Ferrandino, Rocco M.
    Futran, Neal
    Laramore, George E.
    Liao, Jay J.
    Parvathaneni, Upendra
    Panjwani, Neil
    Martins, Renato G.
    Rodriguez, Cristina P.
    Wu, Qian
    BMC CANCER, 2024, 24 (01)
  • [4] Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma
    Chang, Hui-Chin
    Gau, Shuo-Yan
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2025, 151 (02)
  • [5] Changes in serum lactate dehydrogenase as a prognostic factor in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
    Lee, Woo Hee
    Takenaka, Yukinori
    Hosokawa, Kiyohito
    Eguchi, Hirotaka
    Suzuki, Masami
    Fukusumi, Takahito
    Suzuki, Motoyuki
    Inohara, Hidenori
    ACTA OTO-LARYNGOLOGICA, 2024, 144 (5-6) : 398 - 403
  • [6] A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors
    Bonomi, M.
    Bhateja, P.
    Issa, M.
    Klamer, B.
    Pan, X.
    Blakaj, A.
    Karivedu, V
    Mousa, L.
    Mitchell, D.
    Gamez, M.
    Kang, S.
    Seim, Nolan B.
    Old, M.
    Carrau, R.
    Rocco, J.
    Blakaj, D.
    ORAL ONCOLOGY, 2020, 110
  • [7] Expansion cohort validation of a clinical predictive model for head and neck cancer survival in patients treated with immune checkpoint inhibitors.
    Laliotis, Georgios I.
    Issa, Majd
    Klamer, Brett
    Karivedu, Vidhya
    Bhateja, Priyanka
    Dibs, Khaled
    Mladkova, Nikol
    Pan, Xueliang Jeff
    Old, Matthew O.
    Gamez, Mauricio
    Grecula, John C.
    Jhawar, Sachin R.
    Mitchell, Darrion L.
    Baliga, Sujith
    Carrau, Ricardo
    Rocco, James William
    Blakaj, Dukagjin
    Bonomi, Marcelo Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
    Starzer, Angelika Martina
    Heller, Gerwin
    Tomasich, Erwin
    Feldmann, Katharina
    Hatziioannou, Teresa
    Traint, Stefan
    Minichsdorfer, Christoph
    Schwarz-Nemec, Ursula
    Nackenhorst, Maja
    Muellauer, Leonhard
    Preusser, Matthias
    Berghoff, Anna Sophie
    Fuereder, Thorsten
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).
    Alfieri, Salvatore
    Ferrara, Roberto
    Calareso, Giuseppina
    Cavalieri, Stefano
    Platini, Francesca
    Mancinelli, Moela
    Resteghini, Carlo
    Orlandi, Ester
    Iacovelli, Nicola Alessandro
    Ferella, Letizia
    Piazza, Cesare
    Apollonio, Giulia
    Galbiati, Donata
    Bossi, Paolo
    Bergamini, Cristiana
    Locati, Laura Deborah
    Licitra, Lisa F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma-Reply
    Mastrolonardo, Eric V.
    Llerena, Pablo
    Curry, Joseph M.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2025, 151 (02)
12345